

**NATIONAL INSTITUTE FOR HEALTH AND CARE
EXCELLENCE**

HEALTH TECHNOLOGY APPRAISAL PROGRAMME

Equality impact assessment – Scoping

**STA Sotatercept for treating pulmonary arterial
hypertension [ID6163]**

The impact on equality has been assessed during this appraisal according to the principles of the NICE equality scheme.

- | |
|---|
| 1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they? |
|---|

The scope consultation and workshop identified that there could be issues of inequitable access to the specialist services required to administer sotatercept. The technology is administered as a pre-filled injection that is to be used at home, but some people (e.g. with disabilities) may need help to administer, e.g from a specialist nurse. But also, some people who have previously not been able to have IV treatment may now be able to access treatment because sotatercept is self-administered at home. Older patients may be less considered for sotatercept because of an increased risk of bleeding and associated complications. This may also be a consideration for women who are menstruating.

- | |
|---|
| 2. What is the preliminary view as to what extent these potential equality issues need addressing by the committee? |
|---|

These do not constitute equalities issues that will need to be explicitly addressed by committee.

- | |
|--|
| 3. Has any change to the draft scope been agreed to highlight potential equality issues? |
|--|

No

4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the matrix been made?
--

No

Approved by Associate Director (name): Emily Crowe.....

Date: 18/12/2024